Co-Authors
This is a "connection" page, showing publications co-authored by Marcus Schultz and Renfeng Guo.
Connection Strength
0.057
-
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020 Dec; 2(12):e764-e773.
Score: 0.057
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.